ARTICLE

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis

Milica Pavlovic*, Anna Arnal-Estapé*, Federico Rojo, Anna Bellmunt, Maria Tarragona, Marc Guiu, Evarist Planet, Xabier Garcia-Albéniz, Mónica Morales, Jelena Urosevic, Sylwia Gawrzak, Ana Rovira, Aleix Prat, Lara Nonell, Ana Lluch, Joël Jean-Mairet, Robert Coleman, Joan Albanell, Roger R. Gomis

Affiliations of authors: Oncology Program (MP, AAE, AB, MT, MG, XGA, MM, JU, SG, RRG) and Biostatistics and Bioinformatics Unit (EP), Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain; Cancer Research Program (FR, AR, JA) and Microarray Analysis Service (LN), IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Pathology Department, IIS-Fundación Jimenez Díaz, Madrid, Spain (FR); Medical Oncology Service, Hospital del Mar, Barcelona, Spain (AR, JA); Department of Oncology and Hematology, Hospital Clínico Universitario, Valencia, Spain (AL); Valencia Central University, Spain (AL); Inbiomotion, Barcelona, Spain (JIM); Sheffield Cancer Research Centre, Sheffield, UK (RC); Universitat Pompeu Fabra, Barcelona, Spain (JA); Translational Genomics, Vall d’Hebron Institute of Oncology, Barcelona, Spain (AF); Department of Epidemiology, Harvard School of Public Health, Boston, MA (XGA); Institut Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (RRG).

* Authors contributed equally to this work.

Correspondence to: Roger R. Gomis, Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), PBB52 Parc Científic de Barcelona, C/Baldiri i Reixac 10–12, 08028 Barcelona, Spain (e-mail: roger.gomis@irbbarcelona.org).

Abstract

Background: There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could be of clinical interest.

Methods: A de novo unbiased screening approach based on selection of highly bone metastatic breast cancer cells in vivo was used to determine copy number aberrations (CNAs) associated with bone metastasis. The CNAs associated with bone metastasis were examined in independent primary breast cancer datasets with annotated clinical follow-up. The MAF gene encoded within the CNA associated with bone metastasis was subjected to gain and loss of function validation in breast cancer cells (MCF7, T47D, ZR-75, and 4T1), its downstream mechanism validated, and tested in clinical samples. A multivariable Cox cause-specific hazard model with competing events (death) was used to test the association between 16q23 or MAF and bone metastasis. All statistical tests were two-sided.

Results: 16q23 gain CNA encoding the transcription factor MAF mediates breast cancer bone metastasis through the control of PTHrP. 16q23 gain (hazard ratio (HR) for bone metastasis = 14.5, 95% confidence interval (CI) = 6.4 to 32.9, P < .001) as well as MAF overexpression (HR for bone metastasis = 2.5, 95% CI = 1.7 to 3.8, P < .001) in primary breast tumors were specifically associated with risk of metastasis to bone but not to other organs.

Conclusions: These results suggest that MAF is a mediator of breast cancer bone metastasis. 16q23 gain or MAF protein overexpression in tumors may help to select patients at risk of bone relapse.

Women with primary breast cancer (BC) are at risk of distant metastatic relapse many years or decades after surgery. Adjuvant (ie, postoperative) systemic treatments, such as chemotherapy, hormonal therapy (in estrogen receptor–positive tumors [ER+])...
and anti-HER2 therapy (in HER2-positive tumors), may eradicate micrometastatic disease and thereby reduce the risk of metastatic relapse. However, current adjuvant treatments are toxic (particularly chemotherapy), only benefit a subset of women, and the prevention of overt metastasis is non–organ specific. BC is a highly heterogeneous disease, and there is clinical evidence of distinct patterns of disease relapse (1). In fact, the capacity of metastatic BC cells to grow in different environments may give rise to metastatic speciation (2).

The discovery in past years of mediators of organ-specific metastasis in breast and other cancers suggests that it might be possible to identify clinically actionable biomarkers that specifically predict bone metastasis risk in breast cancer. Unbiased testing for recurrent copy number aberrations (CNAs) in large datasets aimed at the identification of bone metastasis risk mediators is a feasible approach that may provide novel data and insights. CNAs have been observed in several human cancers, and these events are usually associated with the presence of mediators of malignancy and clinical outcome, for example 17q12 and the HER2 oncogene (3). However, CNAs associated with tissue-specific metastasis remained uncharacterized.

Here we followed an unbiased screening approach to test the hypothesis that BC metastasizes to the bone by selecting mediators for homing, survival, and colonization that result from genomic alterations. Using this approach, we identified that the 16q23 gain, through the v-maf avian musculoskeletal sarcoma oncogene homolog (MAF) gene, mediates bone metastasis in breast cancer and independently associates with risk of bone metastasis but not metastasis to other sites.

Methods

Cell Culture

The MCF7, ZR-75, and T47D human breast cancer (BC) cell lines and 4T1 murine BC cells were purchased from American Type Culture Collection (ATCC). These cell lines and their genetically modified derivatives were maintained as described previously (4). Cells were maintained in the indicated media as per ATCC guidelines and were routinely tested for well-reported breast cancer markers, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Thus, cells were grown in DMEM or RPMI medium (Gibco), supplemented with 10% fetal bovine serum (FBS) (Biological Industries Kibbutz Beit Haemek, Israel), Glutamine 0.29 mg/mL (Biological Industries Kibbutz Beit Haemek, Israel), Penicillin 100 U/mL (Biological Industries) and Streptomycin 0.1 mg/mL (Biological Industries Kibbutz Beit Haemek, Israel). Further details are given in the Supplementary Methods (available online).

Animal Studies and Xenografts

All animal work was approved by the institutional animal care and use committee of Institute for Research in Biomedicine (IRB) Barcelona and performed following the principles of laboratory animal care (as mandatory per European Union and Local government laws). Female BALB/c nude mice of 11 weeks of age (n = 9–37 per group) were used for all studies. Mice were anesthetized with ketamine (100 mg/kg body weight) and xylazine (10 mg/kg body weight), and after injection imaged mice were monitored weekly using IVIS imaging. Further details are given in the Supplementary Methods (available online).

Oligonucleotide Array Assays

RNA sample collection and generation of biotinylated complementary RNA (cRNA) probe were carried out essentially as described in the standard Affymetrix (Santa Clara, CA) GeneChip protocol. Ten micrograms of total RNA were used to prepare a cRNA probe using a Custom Superscript Kit (Invitrogen Carlsbad, CA). For expression profiling, 25 ng of RNA per sample was processed using isothermal amplification SP6 Biotin System (NuGEN technologies San Carlos, CA). Each sample was hybridized with an Affymetrix Human Genome U133APlus2.0 microarray at the IRB Barcelona Functional Genomics Core Facility. Further details are given in the Supplementary Methods (available online).

Analysis of Copy Number Alterations in Expression Data

The detection of CNAs by means of expression profile analysis is based on strong correlation between the genomic alterations and the aberrant gene expression in the affected genomic regions. While the detection of CNAs using gene expression analysis is possible, difficulties arise from the type of starting expression data (8). We used the function findCopyNumber from the Bioconductor phenoTest package, which implements an approach similar to the one applied by Hu et al. (5) to find regions with CNAs in the MSKCC/EMC cohort. Enrichment scores (in our case log hazard ratios) and the chromosomal positions of the scores allowed us to distinguish areas in which the enrichment was higher/lower than expected when the positions were assigned at random. Further details are given in the Supplementary Methods (available online).

Fluorescence in Situ Hybridization and Other Methods

Cells were processed as described (6). The slides were incubated with MAF probe BAC RP11-1068n20. This probe covered a 197 kb segment at chr16: 79,460,645-79,657,297, a region including the full MAF gene (chr16: 79,625,745 to 79,639,622, 14 kb) and excluding WWOX and the FRA16D fragile site. In parallel, a CEP16 (centromeric chr16, 16q11.2) (Abbot Chicago, IL) probe was used to score 16q23 CNAs. Findings were confirmed with an independent MAF/CEP16 probe (Inbioemotion Barcelona, Spain). DAPI counterstain was applied, and images were acquired with a Leica TCS-SP5 confocal microscope. The percentage of 16q23 CNA–positive cells was determined based on minimum of 100 counted cells for each condition. Information on protein extraction and western blots, chromatin immunoprecipitation, quantitative real-time polymerase chain reaction (qRT-PCR), histopathology and immunohistochemistry, reporter assays, osteoclast differentiation assay, and cell migration and adhesion assays is given in the Supplementary Methods (available online).

Patient Gene Expression Datasets

Information on the patients was downloaded from GEO (7). The following cohorts were used: A) MSKCC/EMC. Pooled GSE2603, GSE2034, and GSE12276; B) GSE14020. ER+ patients were selected on the basis of the bimodality of gene ESR1. C) Patient expression profiles and clinical annotations were downloaded as described in van de Vijver et al. (8). Further details are given in the Supplementary Methods (available online).
Statistical Methods

Cumulative incidence was estimated with Cox proportional hazard models and likelihood ratio tests. The assumption of proportionality was checked using the supremum test for proportional hazards assumption. This test yields a significant P value if this assumption is violated.

Of note, cumulative incidence for validation dataset II was calculated using Cox cause-specific hazard model with competing events (death). Cumulative incidence functions for recurrence were estimated. These functions estimate the actual percentage of patients who will experience the various competing events within the study cohorts as opposed to the overestimated percentages obtained with the Kaplan-Meier method based on the cause-specific hazards.

For survival analyses, a multivariable Cox proportional hazard model was fitted to test the correlation between high MAF-expressing vs the rest of the tumors and bone metastasis. Tumor size, lymph node status, tumor grade, and proliferation were used as adjustment variables. R’s function step was used to perform backward elimination by AIC. P values were obtained with Cox proportional hazards likelihood ratio tests.

Of note, cumulative incidence for validation dataset II was calculated using Cox cause-specific hazard model with competing events (death). Cumulative incidence functions for recurrence were estimated. These functions estimate the actual percentage of patients who will experience the various competing events within the study cohorts as opposed to the overestimated percentages obtained with the Kaplan-Meier method based on the cause-specific hazards.

For survival analyses, a multivariable Cox proportional hazard model was fitted to test the correlation between high MAF-expressing vs the rest of the tumors and bone metastasis. Tumor size, lymph node status, tumor grade, and proliferation were used as adjustment variables. R’s function step was used to perform backward elimination by AIC. P values were obtained with Cox proportional hazards likelihood ratio tests.

Results

Identification of CNAs Associated With Bone Metastasis in BC

We developed an experimental xenograft mouse model based on ER+ moderately bone metastatic MCF7 BC cells to derive cells with higher propensity to metastasize to the bone (9–14). To perform in vivo selection we introduced MCF7 luciferase-expressing...
cells in the left ventricle of BALB/c nude mice and monitored their growth by quantitative bioluminescence imaging. After three rounds of passaging, we selected cells with a statistically higher rate of bone metastasis than parental MCF7 cells, which we termed BoM2 (Figure 1A). The tumor growth when tested by orthotopic injection at the mammary fat pad was similar between parental MCF7 and BoM2 cells, and both were dependent on estrogen gene responses (Supplementary Figure 1, A-C, available online).

We studied genomic copy number aberrations (CNAs) in BoM2 cells by comparative genomic hybridization. We uncovered substantial losses in chromosomes 6, 12, 19, 20, and 21 and one substantial gain (16q22-q24) in BoM2 compared with the parental population (Figure 1B; Supplementary Figure 1D, available online). Using an ACE-like algorithm (Analysis of CNAs by Expression data [5]), we associated variations in CNA with metastasis risk in 349 ER+ primary BC patients (discovery MSKCC/EMC BC set) (12). Only the 16q22-24 chromosomal gain showed a substantial association with metastasis (Figure 1C; Supplementary Figure 1E, available online). This association was confirmed by applying the ACE-like algorithm to an independent validation cohort I (van de Vijver BC set) (Figure 1C) (8). Patients with 16q22-24 CNA-positive ER+ BC tumors (MSKCC/EMC) had a higher cumulative rate of metastasis (hazard ratio [HR] = 1.37, 95% confidence interval [CI] = 1.01 to 1.88, P = .048) (Supplementary Figure 1F, available online). Next, we confirmed 16q23 copy gain in BoM2 cells (98.7% of cells) compared with parental MCF7 cells (8.7% of cells) by means of the ratio of 16q23 and a CEP16 (16q11.2) centromeric FISH probe (Figure 1D). We also characterized additional breast cancer cell lines and showed that they had varying degrees of 16q23 gain (T47D 13.7% and ZR-75 47.5%) (Supplementary Figure 1G, available online).

Association of 16q23 Genomic Gain With Breast Tumors That Develop Bone Metastasis

Next, we tested 16q23 gain by FISH in paraffin-embedded samples from an independent validation set II of primary stage I-III BC specimens from patients with annotated clinical follow-up (Spanish dataset) (15). We found that 14% of the 334 primary BCs tested were classified as positive for 16q23 gain, defined by at least 1.5 copies of the 16q23 region normalized to the CEP16 centromeric probe per cell (a minimum of 50 cells per specimen were scored) (Figure 1E). 16q23 gain–positive tumors were at a high cumulative incidence rate of bone metastasis at any time (HR = 14.5, 95% I = 6.4 to 32.9, P < .001; hazard ratio was calculated considering death before recurrence in bone as a competing event) (Table 1 and Figure 1F; Supplementary Tables 1 and 2, available online).

Table 1. Cumulative incidence of recurrence in bone at any time in patients with 16q23 CNA*

| Variable                  | Univariate (n = 313) | Multivariable (n = 313) |
|---------------------------|----------------------|-------------------------|
|                           | HR (95% CI)          | P                       | HR (95% CI)          | P                       |
| Menopausal status         |                      |                         |                       |                         |
| Premenopausal             | 1.00 (referent)      | .597                    | -                     | -                       |
| Postmenopausal            | 0.81 (0.37 to 1.74)  | .12                     | 1.00 (referent)       | .299                    |
| Tumor size, mm            |                      |                         |                       |                         |
| ≤20                       | 1.00 (referent)      | .12                     | 1.00 (referent)       | .160                    |
| 21–50                     | 1.86 (0.87 to 3.93)  | 1.56 (0.63 to 3.81)     | .56 (0.12 to 2.57)   | .255                    |
| >50                       | 1.73 (0.60 to 5.01)  |                         |                       |                         |
| Tumor grade               |                      |                         |                       |                         |
| I                         | 1.00 (referent)      | .749                    | 1.00 (referent)       | .160                    |
| II                        | 0.87 (0.41 1.83)     | 2.75 (0.32 to 23.33)    | 1.12 (0.12 to 10.27) | .255                    |
| III                       | 1.58 (0.75 to 3.33)  |                         |                       |                         |
| Lymph nodes               |                      |                         |                       |                         |
| None                      | 1.00 (referent)      | .414                    | -                     | -                       |
| 1–3                       | 0.94 (0.41 to 2.14)  | 1.20 (0.46 to 3.11)     | -                     | -                       |
| 4–9                       | 1.27 (0.58 to 4.24)  | 1.79 (0.33 to 9.54)     | -                     | -                       |
| >9                        | 3.39 (1.17 to 9.81)  | 4.57 (1.16 to 18.01)    | -                     | -                       |
| Hormonal receptor status  |                      |                         |                       |                         |
| Negative                  | 1.00 (referent)      | .710                    | -                     | -                       |
| Positive                  | 0.71 (0.52 to 1.57)  |                         | -                     | -                       |
| HER2 status               |                      |                         |                       |                         |
| Negative                  | 1.00 (referent)      | .580                    | -                     | -                       |
| Positive                  | 1.30 (0.52 to 3.22)  |                         | -                     | -                       |
| Proliferation (Ki-67)     |                      | .010                    | .263                  | .041                    |
| Low proliferation (<15%)  | 1.00 (referent)      |                         | 1.00 (referent)       | .263                    |
| High proliferation (>15%) | 2.81 (1.37 to 6.34)  | 1.65 (0.68 to 3.98)     |                         |                         |
| 16q23 (FISH CNA)          | 1x10⁻¹¹              |                         | 3x10⁻¹⁰               |                         |
| Below 1.5                 | 1.00 (referent)      |                         | 1.00 (referent)       |                         |
| Equal or More 1.5         | 14.5 (6.4 to 32.9)   | 18.02 (6.69 to 48.53)   |                         |                         |

* Measured from date of primary tumor surgical resection. Analyzed by Cox cause-specific hazards model with competing events (death before recurrence in bone). The risk of the competing event is reported in Supplementary Table 2 (available online). CI = confidence interval; CNA = copy number aberration; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio.
available online). Moreover, 16q23 gain significantly associated with poor overall survival (OS) (HR for OS = 3.8, 95% CI = 2.0 to 7.4, \( P < .001 \)) and not with other nonvisceral and visceral metastasis (Supplementary Figure 1, H and I, available online).

In this series, 16q23 gain–positive tumors were statistically significantly associated with high-grade larger tumor size and high proliferation (Ki67 > 15%), but not with age, menopausal status, ER, PR, HER2, or lymph node (LN) involvement (Supplementary Table 1, available online). In a multivariable competing risk Cox analysis, combining tumor size, grade, proliferation, LN status, and 16q23 gain, the latter retained a statistically significant hazard ratio of cumulative bone metastasis at any time of 18.02 (95% CI = 6.69 to 48.53, \( P < .001 \)) (Table 1; Supplementary Table 2, available online). Thus, 16q23 gain was an independent marker of bone metastasis, including nodal status (Sensitivity [Se] = 0.71, Specificity [Sp] = 0.88 for cumulative incidence of bone metastasis ever; median follow-up is similar in both categories (Supplementary Table 1 and Supplementary Figure 1I, available online), with a 97% negative predictive value (NPV). The relationship between 16q23 gain and bone metastasis was statistically significant in ER+, triple-negative (TN), and HER2+ tumors (Figure 1F; Supplementary Figure 1K, available online).

**Association of MAF Expression in the 16q23 Region With Bone Metastasis**

We examined possible bone mediators in the 16q23 region by identifying genes that were more than two-fold (\( P < .05 \)) differentially expressed in BoM2 derivatives compared with parental MCF7 cells (Supplementary Figure 2A, available online). Among the two candidates, MAF and SLC9A5 (Supplementary Figure 2, A-D, available online), the Cox hazard ratio for the association of mRNA expression and bone metastasis showed statistical significance for MAF (\( P = .032 \)) but not for the SLC9A5 (\( P = .95 \)) (MSKCC/EMC BC dataset). Patients with BC with high MAF expression showed a greater cumulative incidence of metastasis to bone—but not to brain or lung—than the rest (HR for bone metastasis = 2.5, 95% CI = 1.7 to 3.8, \( P < .001 \)) (Figure 2A; Supplementary Figure 2E, available online). Next, we confirmed MAF gain in 9.1% of the 1079 tumors evaluated by the The Cancer
Genome Atlas BC project (16). This percentage was smaller than in the FISH-validated Spanish dataset II; however, this may be related, at least in part, to the higher sensitivity of our test. MAF, a potential genetic driver of the 16q23 region, is a transcription factor of the AP-1 family that has been reported to contribute to transformation in 60% of Angioimmunoblastic T-cell lymphoma (AITL) (17,18) and 50% of multiple myeloma (MM) patients (19). However, to date, MAF has not been associated with BC cell transformation, tumor progression, or metastasis (20).

To characterize the relationship between MAF and bone metastasis, we analyzed MAF protein expression by immunohistochemistry in the validation dataset II (high MAF defined as >1000 optical density [OD], cutoff determined based on the receiver operating characteristic curve) (Figure 2B; Supplementary Figure 2F, available online). High MAF protein staining was associated with a high cumulative risk of metastasis to bone at any time but not to other nonvisceral and visceral sites (HR for bone metastasis = 4.68, 95% CI = 2.29 to 9.57, P < .001) (Figure 2C and Table 2; Supplementary Tables 3 and 4, available online). MAF protein expression by IHC and 16q23 gain by FISH were correlated (r = 0.52, P < .001) (Figure 2D; Supplementary Figure 2G, available online). MAF protein expression enabled better assignment of positive bone metastasis patients than MAF mRNA expression (Figure 2E). ER+ BC patients with MAF OD above 25 000 developed bone metastasis with almost complete penetrance (sensitivity = 0.36, specificity = 0.99, HR for bone met at any time = 21.3, 95% CI = 8.3 to 54.7, P < .001) (Supplementary Figure 2H, available online). In triple-negative disease, 1000 OD cutoff–identified patients at high risk of bone metastasis (sensitivity = 0.75, specificity = 0.83; HR for bone met at any time = 10.7, 95% CI = 2.2 to 53.3, P = .001) (Supplementary Figure 2H, available online). In HER2+ patients, no statistical significance was achieved (Supplementary Figure 2I, available online). In a multivariable analysis, MAF protein expression retained its predictive value for bone metastasis independently of traditional clinico-pathological parameters (HR for bone metastasis at any time = 5.28, 95% CI = 2.5 to 11.2, P < .001) (Table 2; Supplementary Tables 3 and 4, available online).

### Effect of MAF on BC Metastasis to Bone

Next, we functionally validated the role of MAF in bone metastasis by MAF-stable downregulation or overexpression in a panel of BC cell lines. Interestingly, MAF protein levels in the 16q23 gain–positive BoM2, MCF7 MAF–overexpressing, and ZR-75 cells were comparable with those in 16q23 gain–positive tumors, whereas MCF7 parental, MAF-depleted BoM2, and T47D cells expressed MAF similarly to 16q23 gain–negative

### Table 2. Cumulative incidence of recurrence in bone at any time in patients based on MAF expression (IHC)*

| Variable                      | Univariate (n = 343) | Multivariate (n = 343) |
|-------------------------------|----------------------|------------------------|
|                               | HR (95% CI) | P          | HR (95% CI) | P          |
| Menopausal status             |            |            |            |            |
| Premenopausal                 | 1.00 (referent) | .676       | -          | -          |
| Postmenopausal                | 0.85 (0.40 to 1.80) | .007       | -          | .151       |
| Tumor size, mm                |            |            |            |            |
| ≤20                           | 1.00 (referent) |            | -          |            |
| 21–50                         | 2.13 (1.03 to 4.37) |    | 2.21 (0.95 to 5.13) | .046       |
| >50                           | 1.56 (0.54 to 4.47) |            | 2.34 (0.65 to 8.41) |            |
| Tumor grade                   |            |            |            |            |
| I                             | 1.00 (referent) | .046       | 1.00 (referent) | .121       |
| II                            | 1.42 (0.69 to 2.93) |            | 4.27 (0.55 to 32.99) |            |
| III                           | 1.27 (0.61 to 2.65) |            | 2.37 (0.28 to 19.68) |            |
| Lymph nodes                   |            |            |            |            |
| None                          | 1.00 (referent) | .007       | 1.00 (referent) | .047       |
| 1–3                           | 1.06 (0.47 to 2.39) |            | 1.22 (0.49 to 3.02) |            |
| 4–9                           | 0.63 (0.15 to 2.65) |            | 0.67 (0.14 to 3.23) |            |
| >9                            | 5.14 (2.20 to 11.99) |            | 4.04 (1.46 to 11.15) |            |
| Hormonal receptor status      |            |            |            |            |
| Negative                      | 1.00 (referent) | .167       | -          | -          |
| Positive                      | 0.58 (0.27 to 1.22) |            | -          | -          |
| HER2 status                   |            |            |            |            |
| Negative                      | 1.00 (referent) | .670       | -          | -          |
| Positive                      | 0.81 (0.31 to 2.13) |            | -          | -          |
| Proliferation (Ki-67)         |            |            |            |            |
| Low proliferation (<15%)      | 1.00 (referent) | .014       | 1.00 (referent) | .044       |
| High proliferation (>15%)     | 2.52 (1.23 to 5.18) |            | 2.23 (1.03 to 4.84) |            |
| cMAF (IHC)                    | 5x10⁻⁵     |            | 2x10⁻⁵     |            |
| Nonoverexpression             | 1.00 (referent) |            | 1.00 (referent) |            |
| Overexpression                | 4.68 (2.29 to 9.57) |            | 5.28 (2.50 to 11.20) |            |

* Measured from date of primary tumor surgical resection. Analyzed by Cox cause-specific hazards model with competing events (death before recurrence in bone). The risk of competing events is reported in Supplementary Table 4 (available online). CI = confidence interval; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio; IHC = immunohistochemistry.
tumors (Figure 3A; Supplementary Figure 3, A and B, available online).

Orthotopically implanted mock and MAF-overexpressing MCF7 and T47D cells in mice grew similarly, indicating that MAF did not contribute to proliferation, but the MAF-expressing groups showed enhanced bone metastatic capacity (Figure 3B; Supplementary Figure 3, C-G, available online). Consistently, only 23% of the mice inoculated via the left ventricle with BoM2 MAF knockdown cells developed bone metastasis detectable by luciferase activity at day 54 postinjection, compared with 90% in the shControl BoM2 cells or 50% in the shMAF BoM2 cells with rescued MAF expression (Figure 3C; Supplementary Figure 3, C and D, available online). The reduction in bone metastasis in MAF-depleted cells was accompanied by a decrease in the extent of hind limb lesions, as determined by photon flux ex vivo and histomorphometric analysis (Figure 3C; Supplementary Figure 3H, available online). In contrast, MAF overexpression (Supplementary Figure 3, C-E, available online) enhanced the capacity of MCF7 to metastasize to bone (Figure 3D; Supplementary Figure 3, I and J, available online) but did not support lung or adrenal colonization in different experimental settings (Supplementary Figure 3, K and L, available online).

Similar results were observed in T47D cells that are poorly metastatic (9,10). Inoculation of T47D MAF-overexpressing cells statistically significantly reduced bone metastasis–free survival (Figure 3E; Supplementary Figure 3, A, B, and M, available online) but did not influence metastasis rate in other sites (Supplementary Figure 3, N and O, available online). Upon hindlimb implantation, MAF expression increased bone colonization of T47D (ER+) (Figure 3F) and 4T1 (triple-negative) cells (Supplementary Figure 3P, available online), whereas MAF depletion in ZR75 (ER+) cells impaired this process (Figure 3G). Collectively, these results confirmed MAF as a mediator of bone metastasis in the various BC cells.

Figure 3. MAF mediation of bone metastasis in breast cancer (BC) cells. A) MAF protein log2 score (immunohistochemistry [IHC], optical density values) on the vertical axis and various BC patient samples (n = 20) and BC cell lines (n = 10–20 sections) on the horizontal axis were plotted. Amplified (red) and not-amplified (green) categories are highlighted. B) Bone metastasis was scored from MAF-overexpressing and control parental cells implanted in the mammary fat pad. Mice bearing size-matched tumors (>300 or >100 mm³ for MCF7 or T47D, respectively) at day 42 were considered when evaluating bone metastasis. Individual tumors are represented as box plots with median, interquartile range, and min and max values. Bone colonization incidence is plotted. P value scored by two-sided Wilcoxon signed-rank test. C) Schematic representation of injection via left ventricle. Kaplan-Meier curve of bone metastasis-free survival for BoM2 shControl, shMAF, and rescue cells. P value was obtained using two-sided log-rank test. Representative bioluminescent images and hematoxylin and eosin (H&E) staining at days 0 and 54 (endpoint) of bone metastasis for each group are shown. T = tumor area. 500 and 50 μm scale bars were used for middle and right panels, respectively. Histomorphometric analysis of bone metastasis lesions is depicted (BV = bone area; TV = tumor area). P values scored by two-sided Wilcoxon signed-rank test. *<.05, **<.01, ***<.001. D) Kaplan-Meier curves of bone metastasis-free survival for MCF7 parental and MAF-overexpressing cells injected via left ventricle of mice. P value was obtained using two-sided log-rank test. E) Kaplan-Meier curve of bone metastasis-free survival for T47D parental and MAF-expressing cells injected via left ventricle of mice. P value was obtained using two-sided log-rank test. F) Bone colonization incidence 14 days postintratibiae inoculation of cells in mice. Two-sided Fisher test was used to score significance. G) Bone colonization incidence 28 days postintratibiae inoculation of ZR-75 control and MAF short hairpin carrying cells. Two-sided Fisher test was used to score significance. BC = breast cancer; CI = confidence interval; ER = estrogen receptor; H&E = hematoxylin and eosin; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio; OD = optical density.
MAF-Induced BC Cell–Bone Stroma Interactions

We combined two independent analyses to identify genes that were transcriptional targets of MAF-short and/or -long isoforms and whose expression in a BC metastasis sample set was significantly correlated with MAF expression. First, we identified genes significantly up or downregulated upon MAF-short and/or -long overexpression in MCF7 cells. Subsequently, we eliminated those genes in the list whose expression was not significantly correlated ($P \geq .05$) with MAF expression in BC metastasis patient samples (GSE14020; liver, brain, bone, and lung BC metastasis sample dataset) (Figure 4A) (21). The resulting 148 putative MAF target genes were named MAF metastasis program (Supplementary Table 5, available online), and, of those, 25 genes were common targets of MAF-short and -long isoforms (Figure 4A; Supplementary Figure 4A, available online). The expression pattern of some of these genes in MAF-expressing cells was confirmed by qRT-PCR analysis (Figure 4B). These results suggested that MAF transcriptionally controls a collection of events that may broadly support functions required for bone metastasis, such as migration (Figure 4C; Supplementary Figure 4B), adhesion to bone marrow–derived cells (Figure 4D), and osteoclast differentiation (Figure 4E; Supplementary Figure 4C, available online).

In size-matched bone metastatic lesions, MAF expression resulted in an increased number of activated tartrate-resistant acid phosphatase multinucleated osteoclasts (TRAP+ cells) along the lesion perimeter (Figure 5A). We then examined the known mediator of bone stroma–tumor interactions PTHrP (parathyroid hormone-related protein) (22) that is one of the MAF metastasis program genes (Figure 5B; Supplementary Figures 4A and 5A, available online) (23,24). Bone metastasis co-expressed high MAF and PTHrP in 77% of the specimens tested (Figure 5C). MAF-enhanced induction of osteoclast differentiation from bone marrow–derived cells in vivo was suppressed upon co-incubation with a PTHrP antagonist peptide (PTHrP-AN) (Supplementary Figure 4C, available online).

Figure 4. MAF regulation of expression of genes associated with bone metastasis in breast cancer (BC). A) Discovery path for the identification of genes whose expression is up- or down-regulated in MAF short- and/or long-expressing cells compared with parental Mock-MCF7 cells. Pearson correlation and fold change bigger than two and Bayesian false discovery rate below 5%. B) Expression levels of genes identified in (A) parental control, MAF-short and MAF-long isoform-overexpressing cells measured by quantitative real-time polymerase chain reaction using indicated TaqMan or SybrGreen probes. B2M or b-ACTIN were used as normalization controls. Data is mean of three experiments with SD. C) Representative images from three independent experiments show wound-closing assay at initial and end timepoints. The extent of wound closure was assessed after 48 hours. Scale bar = 200 μm. D) Representative image of attached green-labeled tumor cells to monolayer of BMSC. Data from three independent experiments is presented as average with SD. P value scored by two-sided Wilcoxon signed-rank test. Scale bar = 500 μm. E) Quantification of the number of TRAP+ differentiated multinucleated (>3 nuclei) osteoclasts per field, normalized to control; representative images are shown. Scale bar = 100 μm. Conditioned media from the indicated cellular populations were used. Data are means from three independent experiments with SD. P value scored by two-sided Wilcoxon signed-rank test.
Previous studies showed that both \( MAF \) and \( PTHrP \) play a role in chondrocyte formation (25, 26), thus suggesting a potential relationship between these genes. We addressed whether \( PTHrP \) and \( MAF \) had direct interaction in bone metastasis and/or human BC, because this possibility had not been reported to date. We confirmed that the -3401/-2421bp \( PTHrP \) P1 promoter, containing a MARE-binding region, increased activity by over-expression of \( MAF \). No effect of \( MAF \) on other \( PTHrP \) promoter regions was seen (Figure 5D and E). Mutations that disrupt all MARE binding sites (Mutant 6) abrogated \( PTHrP \) P1 promoter response to \( MAF \) (Figure 5F). Evidence of a direct interaction was obtained by chromatin immunoprecipitation (ChIP) analysis, with \( MAF \) binding observed at P1 but not at the P2/3 proximal promoter region (Figure 5G).

Next, we sought to validate the contribution of \( PTHrP \) to \( MAF \)-driven bone metastasis in BC cells. We reduced \( PTHrP \) function in \( MAF \)-expressing MCF7 cells by shRNA (Supplementary Figure 5B, available online) or used systemic \( PTHrP \)-AN. \( MAF \)-expressing \( PTHrP \)-depleted cells had impaired ability to form bone metastases but not metastases at other sites (Figure 6A; Supplementary Figure 5C, available online). Similarly, \( PTHrP \) downregulation blunted the capacity of BoM2 cells to colonize the bones (Figure 6B) but not other distant sites (Supplementary Figure 5D, available online). Consistent with the concept that the interaction of breast cancer cells with the niche was central to \( MAF \)-mediated bone colonization, depletion of \( PTHrP \) or treatment with \( PTHrP \)-AN in BoM2 and MCF7/\( MAF \)-overexpressing cells not only decreased the number of bone metastasis but also osteoclasts (TRAP+ cells) along the lesion perimeter (Figure 6, C-E; Supplementary Figure 5, E and F, available online). Collectively, these results support the hypothesis that \( MAF \)-mediated \( PTHrP \) expression is an important factor for the \( MAF \)-driven metastasis tumor cell–stroma interactions that foster BC bone metastasis.

**Discussion**

We provide novel evidence on the association of 16q23 gain to high risk of bone relapse in patients with early BC. We also show that \( MAF \), a gene within this genomic gain, drives the molecular processes of bone colonization. Interestingly, the acquisition of

![Figure 5](https://academic.oup.com/jnci/article-abstract/107/12/djv256/2457717)  
**Figure 5.** \( MAF \) transcriptional control of bone-modifying cytokine \( PTHrP \).  
(A) Upper left panel: Quantification of TRAP+ cells per bone perimeter along the bone-tumor interface of metastasis. Data are presented as box plots with median, interquartile range, and min and max values. Lower left panel: Ex vivo quantification of the size-match bone metastasis. \( P \) value scored by two-sided Wilcoxon signed-rank test.  
(B) \( PTHrP \) expression levels measured by quantitative real-time polymerase chain reaction in MCF7 parental, BoM2, and \( MAF \)-overexpressing cells. Data are means from three independent experiments with SD. \( P \) values scored by two-sided Wilcoxon signed-rank test.  
(C) Dot chart of the standardized mRNA expression of \( MAF \) against the standardized mRNA expression of \( PTHrP \) in human breast cancer (BC) metastasis (GSE14020). The red dots depict bone, and black dots soft tissue metastasis. The blue dotted lines show the average \( MAF \) or \( PTHrP \) expression. Table represents the proportion of bone metastases in each quadrant above.  
(D) Schematic representation of the \( PTHrP \) promoter regions (P1 and P2/P3) and regions amplified in ChIP assays (primer sets, PR1, and PR4). The nucleotide sequence of the human \( PTHrP \) MAF response element (MARE) is shown (green box).  
(E) Luciferase activity of \( PTHrP \) promoter, P1, or P2/3, reporter plasmid in MCF7 cells transfected with control or \( MAF \)-short and -long isoforms expressing vectors normalized to control condition. Data are means from three independent experiments with SD.  
(F) Luciferase activity of mutant \( PTHrP \) P1 promoter reporters in MCF7 cells normalized to wild-type. Data represented from three independent experiments are shown.  
(G) ChIP assays of parental, \( MAF \)-expressing, and BoM2 MCF7-derivative cells performed with the indicated antibodies and polymerase chain reaction primers. \( PTHrP \) promoter proximal region (P2/P3) and the \( \beta \)-ACTIN promoters were used as a negative control. BC = breast cancer; PCR = polymerase chain reaction; WT = wild-type.
high MAF expression parallels that observed in MM and AITL, where several copies of the MAF genomic region or a t(14;16) translocation are gained, leading to transformation and aggressive osteolytic bone colonization (20). These observations suggest that the biology of metastasis mechanisms to the bone may rely on a common mediator that exerts similar or different functions depending on the tumor of origin.

Our results show that MAF controls the expression of a set of genes that collectively support several steps of BC cell metastasis to bone through a series of cell-autonomous and niche-related functions (27). These observations open up the possibility of using MAF as a molecular target for the prevention or treatment of bone metastasis (28). Among the MAF target genes, we identified PTHrP. Whereas PTHrP expression in primary tumors is associated with risk of bone metastasis in T4 and positive nodal status–primary BC (29), it failed to predict bone metastasis in early stage breast tumors (30). These results suggest that PTHrP per se is not sufficient to trigger bone metastasis in early stage BC unless a higher degree of transformation (T4 and positive nodal status) is present. Consistently, our results suggest that only within the right context, for example MAF gain leading to the acquisition of various functions that support bone metastasis such as migration, adhesion, etc., does PTHrP expression become an advantage to cancer cells that colonize the bone.

This study also had some limitations. Currently there are no mouse models of breast cancer bone metastasis, making it difficult to extrapolate our experimental results into the clinical setting. In addition, in some of the models analyzed we scored for metastatic bone colonization rather than metastasis from the breast primary site to the bone. Thus, particular focus on the late steps of colonization was unavoidable. The identification of novel drivers of breast cancer bone metastasis, being tested in clinically relevant samples, allows overcoming these limitations.

Our preclinical findings, as well as results from a clinical discovery series, led us to test 16q23 gain by FISH in paraffin-embedded samples from patients with primary BC and clinical follow-up. We detected 16q23 CNA in 14% of a total of 334

Figure 6. PTHLH contributes to MAF driven bone metastasis in breast cancer (BC). A) Kaplan-Meier curve of bone metastasis–free survival for shControl or shPTHrP MCF7 parental MAF-expressing cells injected into the left ventricle. P value was obtained using two-sided log-rank test. B) Kaplan-Meier curve of bone metastasis–free survival for shControl or shPTHrP BoM2 cells injected via left ventricle. P value was obtained using log-rank test. C) Quantification of TRAP+ cells per tumor bone (TB) perimeter along the bone-metastasis interface. Data are presented as box plots with median, interquartile range, and min and max values. Ex vivo quantification of the size-matched bone metastasis analyzed was determined. Scale bar = 20 μm. Histomorphometric analysis of bone metastasis lesions is depicted (BV = bone area; TV = tumor area). Data are means, and error bars are standard deviations. P values scored by two-sided Wilcoxon signed-rank test, *<.05. D) Schematic representation of the experiment. Quantification of ex vivo bioluminescent signal at hind limbs at day 54 with representative images for indicated experimental groups. Data are presented as box plots with median, interquartile range, and min and max values. Ex vivo quantification of the size-matched bone metastasis analyzed was determined. Scale bar = 20 μm. Histomorphometric analysis of bone metastasis lesions is depicted (BV = bone area; TV = tumor area). Data are means, and error bars are standard deviations. P values scored by two-sided Wilcoxon signed-rank test, *<.05. F) Model showing how 16q23 DNA genomic gain identifies breast primary tumors that will metastasize to the bone. ER = estrogen receptor.
primary BC specimens and showed that it had a statistically significant and independent association with the risk of bone metastasis. This observation is in agreement with the expected frequency of BC patients who develop bone metastasis (10%–20%) after a 15-year follow-up (1, 31). The 16q region contains a well-defined fragile site (FRA16) located at the FOR (WWOX) locus (32). Alterations on FRA16 are observed in various tumor types with diverse clinical outcome associations; 16q loss of heterozygosity (33), as well as 1q gain/16q loss (34), was associated with a positive outcome in luminal BC (3); 16q loss was related to prostate cancer progression (35), and 16q gain with poor outcome in MM (19). In tumor cells, fragile sites have been associated with translocations, deletions, amplifications, and integration sites (36,37), which might explain the promiscuity of this region.

In addition, we developed an immunohistochemical assay to detect MAF expression. In primary tumors, MAF protein levels measured by IHC and 16q23 gain by FISH were significantly correlated, and both were associated with a high cumulative incidence of metastasis to bone but not to other nonvisceral or visceral sites. On the basis of the mechanistic and clinical data presented above, we propose that the 16q23 gain is selectively associated with bone metastasis risk in early-stage BC and that MAF encoded within this region mediates BC metastasis to bone (Figure 6F). This novel finding may enable the identification of patients at high risk of bone metastasis in a timely fashion. Clinical trials involving thousands of patients have tested or are currently testing the capacity of bisphosphonates or denosumab to prevent bone metastasis. The results of these trials have not yet influenced routine clinical practice (38–40).

In an era of personalized medicine, the incorporation of a biomarker to identify those individuals most likely to benefit from bone-targeted agents is urgently needed (41). Testing 16q23 gain and MAF protein expression in breast cancer specimens from patients included in these trials to assess their predictive value to select patients who benefit from adjuvant bone-modified agents is warranted (42).

Funding

MP and SG is supported by “La Caixa” PhD fellowship program. AAE and AB hold PhD fellowships from the Spanish Ministerio de Ciencia e Innovación (MICINN). MTS is supported by the IRB Barcelona PhD program. JU is a “juan de la Cierva” Researcher (MICINN). FIS PI12/00680, PI12/01552, and PI12/01421 supported JA, AL, and FR, respectively. JA, AL, and AP were part of RD12/0036/0051, RD12/0036/0070, and RD12/0036/0042, and FR is part of biobanc RD09/0076/0010. JA and FR are recipients of intensification grant ISCIII, 2005SGR321, XBTC, MARBiobanc, and Cellex. RRG was supported by the Institució Catalana de Recerca i Estudis Avançats. Support and structural funds were provided by the BBVA Foundation, the Generalitat de Catalunya (2014 SGR 535), and the Spanish Ministerio de Ciencia e Innovación (MICINN) (SAF2013-46196) to RRG.

Notes

We would like to thank the Functional Genomics, Microscopy, and Cytometry core facilities of Institute for Research in Biomedicine (IRB) Barcelona and the UB. We thank David L. Lacey, Angel R. Nebreda, and David Rosell for critical reading of the manuscript.

Author Contributions: MP designed and performed experiments, analyzed experimental and patient data, and participated in manuscript preparation. AAE designed and established the model system and performed microarrays and FISH. FR did the pathological analysis and contributed to the Spanish dataset. MT established the model system. EP adapted the ACE-like algorithm and provided support for the statistical studies of patient data. XGA reviewed all the statistical analyses. MM, SG, AB, and JU performed the experiments. MG performed the experiments with animal models. AR and ALL assisted with the collection of samples from Spanish patients. AP did the analysis using the The Cancer Genoma Atlas breast cancer data. RC, LN, and JM participated in text preparation. JA assisted with the collection of samples from Spanish patients, clinico-pathological correlation, and text preparation. RRG conceived and designed the project, analyzed data, supervised the overall project, and wrote the manuscript.

RRG declares shares of Inbiomotion SL for a value of less than $10 000. Inbiomotion SL develops part of the technology described herein.

References

1. Kennecke H, Verhulst R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2012;28(20):3271–3277.
2. Nguyen IX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–284.
3. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352.
4. Tarragona M, Pavlovic M, Arnal-Estape A, et al. Identification of NOG as a specific breast cancer bone metastasis-supporting gene. J Biol Chem. 2012;287(25):21346–21355.
5. Hu G, Chong RA, Yang Q, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell. 2009;15(1):9–20.
6. Arnal-Estape A, Tarragona M, Morales M, et al. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPα isoforms. Cancer Res. 2010;70(23):9927–9936.
7. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: mining tens of millions of expression profiles—database and tools update. Nucleic Acids Res. 2007;35(Database issue):D760–D765.
8. van de Vijver MJ, He YD, van’De Vijver L, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009.
9. Lu X, Mu E, Wei Y, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha5beta1-positive osteoclast progenitors. Cancer Cell. 2011;20(6):701–714.
10. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2005;102(19):10954–10959.
11. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537–549.
12. Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459(7249):1005–1009.
13. Cheung WK, Zhao M, Liu Z, et al. Control of alveolar differentiation by the lineage transcription factors GATA6 and HOXPI inhibits lung adenocarcinoma metastasis. Cancer Cell. 2013;23(6):725–738.
14. Vanharanta S, Shu W, Brenet F, et al. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med. 2013;19(1):50–56.
15. Rojo F, Garcia-Parras J, Zazo S, et al. Nuclear PARP-1 protein expression is associated with poor overall survival in early breast cancer. Ann Oncol. 2011;22(5):1156–1164.
16. Cancer Genome Atlas Network. Comprehensive molecular portraits of human cancer genomes. Nature. 2012;490(7418):61–70.
17. Morito N, Yoh K, Fujioka Y, et al. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res. 2003;63(6):537–549.
18. Murakami YJ, Yatake Y, Sakaguchi T, et al. c-Maf expression in angiogenic T-cell lymphoma. Am J Surg Pathol. 2007;31(3):1695–1702.
19. Hurt EM, Wietsner A, Rosenwald A, et al. Overexpression of c-maf contributes to T-cell lymphoma in both mice and human. Cancer Res. 2006;66(2):812–819.
20. Yin J, Jiang H, Liu J, et al. c-Maf expression in myelomas characterizes a specific breast cancer bone metastasis supporting gene. Proc Natl Acad Sci U S A. 2008;105(56):21961–21966.
21. Guay TA, Yin JY, Thomas RJ, et al. Parathyroid hormone-related protein (PTHR1)−/−is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone. 2002;30(5):670–676.
23. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401–419.

24. Guise TA, Kozlow WM, Hersh-Herzig A, et al. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer. 2005;5(Suppl2):S46–S53.

25. MacLean HE, Kim JJ, Glimcher MJ, et al. Absence of transcription factor c-maf causes abnormal terminal differentiation of hypertrophic chondrocytes during endochondral bone development. Dev Biol. 2003;262(1):51–63.

26. Lanske B, Karaplis AC, Lee K, et al. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science. 1996;273(5275):663–666.

27. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007;8(5):341–352.

28. Eckhardt BL, Francis PA, Parker BS, et al. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012;11(6):479–497.

29. Takagaki K, Takahashi T, Onoda N, et al. Parathyroid hormone-related protein expression, in combination with nodal status, predicts bone metastasis and prognosis of breast cancer patients. Exp Ther Med. 2012;3(6):963–968.

30. Henderson MA, Danks JA, Slavin JI, et al. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res. 2006;66(4):2250–2256.

31. Yerushalmi R, Woods R, Kennecke H, et al. Patterns of relapse in breast cancer: changes over time. Breast Cancer Res Treat. 2010;120(3):753–759.

32. Chang NS, Doherty J, Ensign A, et al. Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses. Biochem Pharmacol. 2003;66(8):1347–1354.

33. Hansen LL, Yilmaz M, Overgaard J, et al. Allelic loss of 16q23.2–24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res. 1998;58(10):2166–2169.

34. Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009;15(2):441–451.

35. Harkonen P, Kyllonen AP, Nordin S, et al. Loss of heterozygosity in chromosomal region 16q24.3 associated with progression of prostate cancer. Prostate. 2005;62(3):267–274.

36. Myllykangas S, Himberg J, Rohling T, et al. DNA copy number amplification profiling of human neoplasms. Oncogene. 2006;25(55):7324–7332.

37. Coquelle A, Pipiras E, Toledo F, et al. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell. 1997;89(2):215–225.

38. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15):1396–1405.

39. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631–641.

40. NCT01077154. US National Library of Medicine. ClinicalTrials.gov.

41. Coleman RE. Bone cancer in 2011: Prevention and treatment of bone metastases. Nat Rev Clin Oncol. 2011;9(2):76–78.

42. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446–1452.